Clinical Trial Update: MONET1-MOtesanib NSCLC Efficacy and Tolerability Study [Phase 3]

View source ↗

Summary

The MONET1-Motesanib NSCLC Phase 3 trial was terminated, with the update noting the status but not providing results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• motesanib (motesanib)

Snippet

Sponsor: Amgen | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: TERMINATED